Research programme: chimeric antigen receptor T-cell therapeutics - CelyadAlternative Names: CAR NKp/B7H6; CAR-NKp30/B7H6; NKR-3 Allogeneic; NKR-3 Autologous; TCR-deficient NKR T-cell therapy - Celyad
Latest Information Update: 04 Mar 2016
At a glance
- Originator Dartmouth College
- Developer Celyad
- Class CAR-T cell therapies
- Mechanism of Action B7 antigen modulators; Immunostimulants; Natural cytotoxicity triggering receptor 3 modulators; Natural killer cell modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer